Are These 3 CBD Penny Stocks a Good Buy Right Now?

cbd penny stocks

Over the past months, the cannabis sector has struggled to a fair degree, but companies involved in CBD have generally experienced growth in sales. Investing in CBD penny stocks could prove to be a clever strategy since it is a growing sector, and many of the penny stock companies could eventually become major players. There is a widespread belief that due to the wellness functions of CBD, the industry could grow into a multibillion industry before long.

As a matter of fact, leading consultancy firm Ernst & Young has estimated that the CBD space could grow into an $11 billion industry by 2025. In such a situation, having a look at some of the CBD penny stocks in the market could be a prudent strategy. The recent turmoil in the markets has resulted in some stocks being available at steep discounts, and that could also be a factor when it comes to choosing the right CBD stock.

CBD Penny Stocks to Watch: Aphria Inc (TSX:APHA) (NYSE:APHA)

cbd penny stocks

Over the past year or so, Aphria has emerged as one of the more promising cannabis stocks in the industry. The company has one of the strongest cash positions in the industry, and that should work to its advantage in the near-term. Aphria will declare its financial results for the quarter ended February 29 in mid-April, so investors will want to keep an eye out for that.

>> 3 Cheap Marijuana Stocks to Consider After the Panic Selling

In January, Aphria managed to get the coveted European Union Good Manufacturing Practices certifications, and while that is definitely a positive, it is unlikely that it had much of an impact on the company’s revenue for the quarter. However, analysts believe that the current lockdowns in North America are going to be a boost for Aphria's sales. People cooped up at home are ordering more cannabis and CBD products. This notion appears to have prompted a rally in Aphria stock.

That being said, the company doesn't do a ton of direct sales, so it remains to be seen what sort of effect the lockdown period will have on Aphria’s sales figures.

CBD Penny Stocks to Watch: HEXO Corp (TSX:HEXO) (NYSE:HEXO)

HEXO has been in trouble for quite some time, and recently, it became abundantly clear that the company is facing a significant cash crunch. Management released a notice last month expressing concerns about HEXO's continued business. The pandemic has sent capital markets into a tailspin, and there are growing fears that HEXO might not be able to take care of its financial obligations over the coming 12 months.

In February, HEXO managed to get a syndicated credit facility worth $65 million from the Bank of Montreal and Canadian Imperial Bank of Commerce. The company managed to draw $35 million, but after that, the terms were changed. The new terms stipulated that HEXO would have to raise a minimum of $15 million by April 10. The company is clearly in financial trouble, so the April 10 deadline will, no doubt, be watched quite closely by market participants.

There is a massive liquidity risk with the company at this point, so it will be important for investors to keep an eye on the developments in the coming days.

CBD Penny Stocks to Watch: Organigram Holdings (TSX:OGI) (NASDAQ:OGI)

cbd penny stocks

Organigram Holdings has emerged as one of the more promising stocks in the cannabis sector in recent times. The company is aiming to release its financial results for the fiscal second quarter for 2020 at some point in the middle of April. There is a lot to look for in these financial results.

In the previous quarter, which included the three months that ended in November 2019, the company generated revenue of $25.2 million. That reflected a year-on-year rise of more than 100% and a sequential rise of 54%. Gross margins remain modest at 37% following fair value adjustments, but Organigram did manage a positive EBITDA of $4.9 million.

In the upcoming quarter, it will be interesting to see what the company’s cash cost per gram figure will be. In the previous quarter, it led the industry with $0.61 cash cost per gram. International and wholesale sales made up 38% of the revenue in Q1 2020, but it remains to be seen if there is any improvement in Q2 2020.

>> Read More Hemp News

>> Read More Penny Stock News

Featured image: Pixabay

Please See Disclaimer

If You Liked This Article Click To Share

Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of or its officers. The author is wholly responsible for the validity of all statements. was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. does not render general or specific investment advice. Any information on should not be considered a recommendation to buy or sell any security. does not endorse or recommend the business, products, services or securities of any company mentioned on

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.